Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Average Rating of Moderate Buy by Brokerages

Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) have received a consensus recommendation of “Moderate Buy” from the twenty-one analysts that are presently covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation, ten have issued a buy recommendation and one has assigned a strong buy recommendation to […]

Related Keywords

San Diego ,California ,United States ,Canada ,Williamh Rastetter ,Kevinc Gorman ,Neurocrine Biosciences ,Wyliew Vale ,Nasdaq ,Royal Bank ,Acadian Asset Management ,Wells Fargo Company ,Neurocrine Biosciences Company Profile ,Bessemer Group Inc ,Kb Financial Partners ,Neurocrine Biosciences Inc ,Covestor Ltd ,Piershale Financial Group Inc ,Get Rating ,Biosciences Trading Down ,Director William ,Asset Management ,Financial Group ,Neurocrine Biosciences Daily ,Nasdaq Nbix ,Nbix ,Medical ,64125c10 ,Ratings ,Consensus ,